Effects of somatostatin on plasma glucose and glucagon levels in human diabetes mellitus. Pathophysiologic and therapeutic implications.
D000328:Adult; D001786:Blood Glucose / Q000378:metabolism*; D003864:Depression, Chemical; D003920:Diabetes Mellitus / Q000097:blood* / Q000188:drug therapy / Q000503:physiopathology / Q000628:therapy; D005260:Female; D005934:Glucagon / Q000097:blood* / Q000378:metabolism; D013006:Growth Hormone / Q000097:blood / Q000378:metabolism; D013007:Growth Hormone-Releasing Hormone / Q000037:antagonists & inhibitors*; D006801:Humans; D007003:Hypoglycemia / Q000188:drug therapy; D007016:Hypophysectomy; D007275:Injections, Intravenous; D007279:Injections, Subcutaneous; D007328:Insulin / Q000008:administration & dosage / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010179:Pancreas / Q000378:metabolism; D010455:Peptides / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use
D001786:Blood Glucose; D007328:Insulin; D010455:Peptides; D013006:Growth Hormone; D005934:Glucagon; D013007:Growth Hormone-Releasing Hormone